

Touro Scholar

NYMC Faculty Publications

Faculty

9-1-2018

The Role of Acetyl Cysteine in Cocaethylene (Non-Acetaminophen) Acute Liver Failure

Getaw Hassen
New York Medical College

Amaninder Dhaliwal

Catherine A. Jenninigs

Hossein Kalantari
New York Medical College

Follow this and additional works at: https://touro scholar.touro.edu/nymc_fac_pubs



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Hassen, G., Dhaliwal, A., Jenninigs, C., & Kalantari, H. (2018). The Role of Acetyl Cysteine in Cocaethylene (Non-Acetaminophen) Acute Liver Failure. *Case Reports in Emergency Medicine*, 2018, Art. ID.: 4393064. <https://doi.org/10.1155/2018/4393064>

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact daloia@nymc.edu.

Case Report

The Role of Acetyl Cysteine in Cocaethylene (Non-Acetaminophen) Acute Liver Failure

Getaw Worku Hassen ¹, Amaninder Dhaliwal,² Catherine Ann Jenninigs,³ and Hossein Kalantari¹

¹NYMC, Metropolitan Hospital Center, Department of Emergency Medicine, New York, NY 10029, USA

²University of Nebraska, Department of Gastroenterology, Nebraska, USA

³Columbia University, Postbaccalaureate Premedical Program, New York, USA

Correspondence should be addressed to Getaw Worku Hassen; getawh@yahoo.com

Received 26 April 2018; Accepted 19 June 2018; Published 26 September 2018

Academic Editor: Vasileios Papadopoulos

Copyright © 2018 Getaw Worku Hassen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acute liver failure can result from acetaminophen overdose, viral infection, toxins, and other disease conditions. Liver transplant is available in limited fashion and the criteria are strict as to who should get an available liver. N-Acetyl Cysteine (NAC) has been used in non-acetaminophen induced liver failure with success. Here we report a case of acute liver failure from cocaethylene that was reversed with NAC along with other medical therapy. *Case Presentation.* A 50-year-old female patient presented to the Emergency Department (ED) with a two-day history of coffee ground vomiting and hematemesis. She reported occasional substance abuse and heavy alcoholism. She reported shortness of breath and chest pain from the recurrent forceful vomiting. The rest of the review of systems was unremarkable except a fall from intoxication. Physical examination revealed anicteric conjunctiva and nontender abdomen and her vital signs were within normal limits. Initial blood work revealed acute liver and renal failure. The patient was started with general medical management and liver transplant service rejected the case due to active substance abuse. She underwent brief hemodialysis and was started on NAC. Over the course of her hospital stay her liver function and kidney function improved significantly and patient was discharged to home. *Conclusion.* In cases where liver transplant is not an option for various reasons including active substance abuse, a trial of N-Acetyl Cysteine may be beneficial and should be considered in the Emergency Department.

1. Introduction

Acute liver failure can result from acetaminophen overdose, viral infection, toxins, and other disease conditions [1–3]. Liver transplant is available in limited fashion and the criteria are strict as to who should get an available liver. In case of acetaminophen induced acute liver failure N-Acetyl Cysteine (NAC) has been used with success [4]. Some case reports indicated that this treatment has also showed promising results in non-acetaminophen induced liver failure [5, 6]. Here we report a case of acute liver failure from cocaethylene (with concomitant use of alcohol and cocaine) that was reversed with NAC alongside general medical therapy, including emergent hemodialysis.

2. Narrative

A 50-year-old female patient presented to the Emergency Department (ED) with a two-day history of coffee ground vomiting and hematemesis. She had not been able to hold down food and was not eating much. She reported occasional cocaine abuse and heavy alcoholism. She also reported shortness of breath and chest pain from the recurrent forceful vomiting and constipation. The rest of the review of systems was unremarkable, other than a fall from intoxication. Physical examination revealed: blood pressure of 147/77 mmHg, respiratory rate of 18 breath per minute, pulse rate of 115 beats per minute, temperature of 97 degree Fahrenheit, and oxygen saturation of 100% on room air. She appeared pale and had

anicteric bilateral temporal subconjunctival hemorrhage and a nontender abdomen. The rest of the physical examination was unremarkable.

Initial blood work revealed a hemoglobin/hematocrit (H/H) of 11.2mg/dL/36.2%, glucose of 35mg/dL, bicarbonate of 7 mmol/mL, and creatinine of 3.1mg/dL with an anion gap of 44. Her liver function test revealed aspartate aminotransferase (AST) 18487U/L, alanine aminotransferase (ALT) 6015U/L, alkaline phosphatase (ALP) 229U/L, total bilirubin 2.499mg/dL, direct bilirubin 2.18mg/dL, albumin 3.3g/dL, lactate 27 mmol/L, a blood alcohol level of 36 mg/dL, and urine toxicology positive for cocaine. International Normalized Ratio (INR) was 3.01 and pH was 7.06. Her acetaminophen level was 5.8mg/dL (normal range: 10-30) and the salicylate level was 3.7mg/dL (normal range: 2.8-20).

Her Model for End-Stage Liver Disease (MELD) score was 19 predicting a 3-month mortality of 6%. The patient was started with dextrose of 50%, protein pump inhibitor with medical intensive care unit (MICU), and gastrointestinal (GI) consultation. She received a PRBC transfusion along with octreotide. Liver transplant service rejected the case due to active substance abuse and, as per GI recommendation, she was started on N-Acetyl Cysteine (NAC).

An extensive work up revealed the following: Hepatitis B, C, and E were nonreactive, thyroid function was within normal limit, with slightly low complement factors 3 and 4, normal myeloperoxidase antibody, normal copper level, slightly elevated CA19, and Alpha Fetoprotein (AFP). Proteinase-3 A and Alpha 1 Antitrypsin negative were negative, and Ceruloplasmin was slightly decreased. The patient had slightly elevated iron level, slightly decreased Tissue Iron Binding Capacity (TIBC), and transferrin saturation of 76%. Tests for mitochondrial antibody, smooth muscle antibody negative, and liver kidney microsomal antibody were negative, and there was low Factor V level. Normal antinuclear and Anti-Streptolysin antibody were normal. No assay was performed to detect cocaethylene as it is not a routine test.

The patient received general medical stabilization and treatment, including brief hemodialysis and treatment with NAC over the course of her hospital stay, and experienced significant improvement and near resolution of both liver and renal function abnormalities. At discharge her laboratory values were as follows: AST 64 U/L, ALT 216 U/L, ALP 142 U/L, creatinine 1.7mg/dL, total bilirubin 1.23mmol/L, direct bilirubin 0.79mmol/L, INR 1.26, H/H 11.5mg/dL/35.6%, ammonia 25Umol/L, and lactate 1.8mmol/L.

The patient was discharged to her home in improved condition and advised to follow up in the outpatient clinic with counseling for alcohol and substance abuse.

3. Discussion

Acetaminophen is the major cause of acute liver failure, but other factors such as viral infection, chronic alcohol abuse, and other toxins and drugs, as well as some medical conditions, lead to liver failure [1-3, 7, 8]. A combination of any of the abovementioned causes poses a greater risk for liver

damage. The toxic effects of the cocaine-alcohol combination have been observed both in Emergency Department (ED) and in inpatient medical units. Ethanol alters the hepatic biotransformation of cocaine, resulting in a novel active metabolite, cocaethylene [9-11]. Oral cocaine was suggested to produce relatively larger concentrations of cocaethylene [12-15]. Drug abusers combine cocaine and alcohol to get intense high and less paranoia when coming off the high [16-18]. Both alcohol and cocaine cause liver toxicity, but cocaethylene appears to be more potent in its toxicity than cocaine [19-22].

Of the various mechanisms of N-Acetyl-P Aminophenol (APAP), acetaminophen, and metabolism approximately 5% to 10% are metabolized by cytochrome P450 system to N-acetyl-p-benzoquinoneimine (NAPQI) [23], a highly reactive molecule that damages hepatocytes by formation of covalent bonds with other intracellular proteins. This reaction is prevented by conjugation with glutathione and subsequent reactions to generate a water-soluble product [24, 25]. Overdose acetaminophen is increasingly metabolized by cytochrome P450 generating NAPQI in amounts that can deplete glutathione. With glutathione depletion and not being replenished faster, NAPQI will begin to accumulate in the hepatocytes resulting in direct hepatocyte damage [3].

Glutathione is important in preventing the accumulation of peroxides and superoxide radicals and is reduced from 70% to 80% in cases of acetaminophen induced liver cell toxicity [26]. There is approximately 20%-40% reduction in glutathione with cocaine-induced liver cell necrosis [27, 28]. On the contrary, overnight fasting causes a 50% reduction in glutathione without associated liver cell damage [29] and glutathione decrease in itself does not explain covalent binding of metabolically active cocaine metabolites to hepatic proteins [30]. These factors imply that there must be other reasons for liver toxicity other than glutathione depletion. N-acetyl cysteine (NAC), a precursor of glutathione, is an effective antidote for APAP poisoning. When administered early after an acute APAP overdose, NAC provides cysteine for the replenishment and maintenance of hepatic glutathione stores, enhances the sulfation pathway of elimination, and may directly reduce NAPQI back to acetaminophen [31, 32]. Some work showed improved transplant-free survival in patients with APAP-induced fulminant liver failure (FHF) [33, 34]. The mechanism here is not the detoxification of NAPQI but rather enhanced recovery. Several different mechanisms seem to contribute to the efficacy of NAC in this setting. NAC improves hepatic perfusion and oxygen delivery and extraction in patients with APAP-induced FHF [35]. Other beneficial effects include scavenging of reactive oxygen and nitrogen species and improved mitochondrial energy production [36, 37]. These beneficial effects of NAC do not seem to be unique to APAP hepatotoxicity [5].

The mechanisms by which cocaine causes liver cell injury appear to be similar to that of liver injury caused by the toxic metabolite of acetaminophen. It is related to production of highly reactive metabolites, with peroxidation, free radical formation, and covalent binding to hepatic proteins. Approximately 10% of cocaine undergoes N-demethylation in hepatocytes by the cytochrome P-450-mixed function

oxidase system, forming norcocaine, a metabolite that elicits significant liver cell damage when injected intraperitoneally in mice [13–15]. This is due to further enzymatic breakdown to N-hydroxynorcocaine and norcocaine nitroxide [38]. Oxidation to the nitrosonium ion showed the latter to be highly reactive with glutathione, serving as catalyst for the conversion of alcohols, amines, and hydroxide ions to aldehydes, ketones, and hydrogen peroxide and causing lipid peroxidation of cell membranes [12, 39–41].

Patients with acute liver failure (ALF) could deteriorate rapidly, and although a minority of patients may recover, the majority require liver transplantation as a life-saving therapy. Patients need to be immediately recognized, optimizing treatment started, and centers for liver transplantation contacted to facilitate the process. Before the era of transplantation, the mortality rate from ALF was greater than 80% [42]. Survival rates have improved significantly with better understanding of the clinical syndrome, earlier recognition, intensive care monitoring, and transplantation [43].

Compared to patients with acetaminophen induced ALF, patient with non-acetaminophen induced ALF have a spontaneous survival rate of 30%. Patients with non-acetaminophen toxicity have limited therapeutic options and the majority of them require transplantation [43, 44]. Unfortunately, there are strict criteria to qualify for liver transplantation and active substance abuse makes a candidate less fit to get transplant. Given the limited therapeutic options and the graveness of the disease, attempt have been made to treat patients with non-acetaminophen ALF using NAC. Few case reports have shown promising results, especially when applied early on in patents with lower coma grades [6, 45–47]. The first prospective, double-blinded, randomized control study with NAC in non-acetaminophen induced liver failure showed a significant improvement in patients with lower-grade encephalopathy. The transplant-free survival for NAC group was higher (40%) than those without NAC (27%) [5].

In summary, even though both alcohol and cocaine can lead to liver toxicity, the acute liver failure is presumed to be from the potent effect of cocaethylen even if no assay was performed to quantify the cocaethylene level. A potential toxic agent is acetaminophen, but with no toxic blood level it is less likely to be the cause of the acute liver failure. N-acetylcysteine offers potential and early treatment options for patients with ALF from non-acetaminophen causes to improve liver function rapidly and in severe cases until transplantation is available .

4. Conclusion

Liver failure is the result of multiple pathological conditions, toxin effects, and viral infection. N-acetylcysteine has been predominantly used for acetaminophen induced liver failure, in some instance, in non-acetaminophen induced liver failure, but it has also had some success in some instance of non-acetaminophen induced liver failure. In cases where liver transplant is not an option for various reasons, including active substance abuse as in this patient's case, a trial of NAC may be beneficial.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank Kell Julliard for editing the manuscript.

References

- [1] L. J. Chun, M. J. Tong, R. W. Busuttill, and J. R. Hiatt, "Acetaminophen hepatotoxicity and acute liver failure," *Journal of Clinical Gastroenterology*, vol. 3, pp. 342–349, 2009.
- [2] B. Pearce and I. S. Grant, "Acute liver failure following therapeutic paracetamol administration in patients with muscular dystrophies," *Anaesthesia*, vol. 63, no. 1, pp. 89–91, 2008.
- [3] W. M. Lee, "Drug-induced hepatotoxicity," *The New England Journal of Medicine*, vol. 349, no. 5, pp. 474–485, 2003.
- [4] W. Klein-Schwartz and S. Doyon, "Intravenous acetylcysteine for the treatment of acetaminophen overdose," *Expert opinion on Pharmacotherapy*, vol. 12, pp. 119–130, 2011.
- [5] W. M. Lee, L. S. Hynan, L. Rossaro et al., "Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure," *Gastroenterology*, vol. 137, no. 3, pp. 856–864.e1, 2009.
- [6] S. Singh, L. S. Hynan, and W. M. Lee, "Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure," *Digestive Diseases And Sciences*, vol. 58, pp. 1397–1402, 2013.
- [7] T. Y. Kim and D. J. Kim, "Acute-on-chronic liver failure," *Clinical and Molecular Hepatology*, vol. 19, pp. 349–359, 2013.
- [8] K. T. Suk, M. Y. Kim, and S. K. Baik, "Alcoholic liver disease: treatment," *World journal of gastroenterology*20, pp. 12934–12944, 2014.
- [9] R. A. Dean, E. T. Harper, N. Dumauval, D. A. Stoeckel, and W. F. Bosron, "Effects of ethanol on cocaine metabolism: Formation of cocaethylene and norcocaethylene," *Toxicology and Applied Pharmacology*, vol. 117, no. 1, pp. 1–8, 1992.
- [10] M. D. Schechter and S. M. Meehan, "The lethal effects of ethanol and cocaine and their combination in mice: implications for cocaethylene formation," *Pharmacol Biochem Behav*, vol. 52, no. v52, pp. 245–248, 1995.
- [11] P. Andrews, "Cocaethylene Toxicity," *Journal of Addictive Diseases*, vol. 16, no. 3, pp. 75–84, 1997.
- [12] G. C. Kanel, W. Cassidy, L. Shuster, and T. B. Reynolds, "Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models," *Hepatology*, vol. 11, no. 4, pp. 646–651, 1990.
- [13] L. E. Perino, G. H. Warren, and J. S. Levine, "Cocaine-induced hepatotoxicity in humans," *Gastroenterology*, vol. 93, no. 1, pp. 176–180, 1987.
- [14] D. H. Van Thiel and J. A. Perper, "Hepatotoxicity associated with cocaine abuse.," *Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism*, vol. 10, pp. 335–341, 1992.
- [15] I. R. Wanless, S. Dore, N. Gopinath et al., "Histopathology of cocaine hepatotoxicity. Report of four patients," *Gastroenterology*, vol. 98, no. 2, pp. 497–501, 1990.

- [16] M. Farre, "Alcohol and cocaine interactions in humans," *The Journal of pharmacology and experimental therapeutics* 266, pp. 1364–1373, 1993.
- [17] E. D. Herbst, D. S. Harris, E. T. Everhart, J. Mendelson, P. Jacob, and R. T. Jones, "Cocaethylene Formation Following Ethanol and Cocaine Administration by Different Routes," *Experimental and Clinical Psychopharmacology*, vol. 19, no. 2, pp. 95–104, 2011.
- [18] E. J. Pennings, A. P. Leccese, and F. A. Wolff, *Effects of concurrent use of alcohol and cocaine*, *Addiction* 97, 2002.
- [19] F. M. Ndikum-Moffor, T. R. Schoeb, and S. M. Roberts, "Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 284, no. 1, pp. 413–419, 1998.
- [20] X. Ponsoda, R. Bort, R. Jover, M. J. Gomez-Lechon, and J. V. Castell, "Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH," *Biochemical pharmacology*, vol. 58, pp. 1579–1585, 1999.
- [21] W. L. Hearn, S. Rose, J. Wagner, A. Ciarleglio, and D. C. Mash, "Cocaethylene is more potent than cocaine in mediating lethality," *Pharmacol Biochem Behav* 39, pp. 531–533, 1991.
- [22] M. J. Valente, F. M. Carvalho, P. G. Bastos, and M. Carvalho, "Contribution of oxidative metabolism to cocaine-induced liver and kidney damage," *Current Medicinal Chemistry*, vol. 19, pp. 5601–5606, 2012.
- [23] S. D. Nelson, "Molecular mechanisms of the hepatotoxicity caused by acetaminophen," *Seminars in Liver Disease*, vol. 10, no. 4, pp. 267–278, 1990.
- [24] H. Jaeschke and M. L. Bajt, "Intracellular signaling mechanisms of acetaminophen-induced liver cell death," in *Toxicological sciences : an official journal of the Society of Toxicology* 89, pp. 31–41, doi, 10.1093/toxsci/kfi336, 2006.
- [25] H. Jaeschke, M. R. McGill, and A. Ramachandran, "Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity," *Drug metabolism reviews*, vol. 44, pp. 88–106, 2012.
- [26] J. R. Mitchell, D. J. Jollow, W. Z. Potter, J. R. Gillette, and B. B. Brodie, "Acetaminophen induced hepatic necrosis. IV. Protective role of glutathione," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 187, no. 1, pp. 211–217, 1973.
- [27] M. A. Evans and R. D. Harbison, "Cocaine-induced hepatotoxicity in mice," *Toxicology and Applied Pharmacology*, vol. 45, no. 3, pp. 739–754, 1978.
- [28] M. L. Thompson, L. Shuster, and K. Shaw, "Cocaine-induced hepatic necrosis in mice—the role of cocaine metabolism," *Biochemical Pharmacology*, vol. 28, no. 15, pp. 2389–2395, 1979.
- [29] O. Strubelt, E. Dost-Kempf, C.-P. Siegers et al., "The influence of fasting on the susceptibility of mice to hepatotoxic injury," *Toxicology and Applied Pharmacology*, vol. 60, no. 1, pp. 66–77, 1981.
- [30] M. A. Evans, "Role of protein binding in cocaine-induced hepatic necrosis," *The Journal of pharmacology and experimental therapeutics*, vol. 224, pp. 73–79, 1983.
- [31] J. H. Lin and G. Levy, "Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats," *Biochemical Pharmacology*, vol. 30, no. 19, pp. 2723–2725, 1981.
- [32] B. H. Lauterburg, G. B. Corcoran, and J. R. Mitchell, "Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo," *The Journal of Clinical Investigation*, vol. 71, no. 4, pp. 980–991, 1983.
- [33] P. M. Harrison, R. Keays, G. P. Bray, G. J. M. Alexander, and R. Williams, "Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine," *The Lancet*, vol. 335, no. 8705, pp. 1572–1573, 1990.
- [34] R. Keays, P. M. Harrison, J. A. Wendon et al., "Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial," *British Medical Journal*, vol. 303, no. 6809, pp. 1026–1029, 1991.
- [35] P. M. Harrison, J. A. Wendon, A. E. Gimson, G. J. Alexander, and R. Williams, "Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure," *The New England journal of medicine*, vol. 324, pp. 1852–1857, 1991.
- [36] T. R. Knight, Y. S. Ho, A. Farhood, and H. Jaeschke, "Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione," *The Journal of Pharmacology And Experimental Therapeutics*, vol. 303, pp. 468–475, 2002.
- [37] C. Saito, C. Zwingmann, and H. Jaeschke, "Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine," *Hepatology*, vol. 51, pp. 246–254.
- [38] M. W. Kloss, G. M. Rosen, and E. J. Rauckman, "Cocaine-mediated hepatotoxicity a critical review," *Biochemical Pharmacology*, vol. 33, no. 2, pp. 169–173, 1984.
- [39] J. C. Charkoudian and L. Shuster, "Electrochemistry of norcocaine nitroxide and related compounds: Implications for cocaine hepatotoxicity," *Biochemical and Biophysical Research Communications*, vol. 130, no. 3, pp. 1044–1051, 1985.
- [40] L. Shuster, E. Casey, and S. S. Welankiwar, "Metabolism of cocaine and norcocaine to N-hydroxynorcocaine," *Biochemical Pharmacology*, vol. 32, no. 20, pp. 3045–3051, 1983.
- [41] L. Shuster, C. A. Garhart, J. Powers, Y. Grunfeld, and G. Kanel, "Hepatotoxicity of cocaine," *NIDA Research Monograph*, no. 88, pp. 250–275, 1988.
- [42] J. Rakela, S. M. Lange, J. Ludwig, and W. P. Baldus, "Fulminant hepatitis: Mayo Clinic experience with 34 cases," *Mayo Clinic proceedings*, vol. 60, pp. 289–292, 1985.
- [43] G. Ostapowicz, R. J. Fontana, F. V. Schiødt et al., "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States," *Annals of Internal Medicine*, vol. 137, no. 12, pp. 947–954, 2002.
- [44] W. M. Lee, R. H. Squires Jr., S. L. Nyberg, E. Doo, and J. H. Hoofnagle, "Acute liver failure: Summary of a workshop," *Hepatology*, vol. 47, pp. 1401–1415, 2008.
- [45] I. Sales, A. L. Dzierba, P. L. Smithburger, D. Rowe, and S. L. Kane-Gill, "Use of acetylcysteine for non-acetaminophen-induced acute liver failure," *Annals of Hepatology*, vol. 12, no. 1, pp. 6–10, 2013.
- [46] G. E. Sklar and M. Subramaniam, "Acetylcysteine treatment for non-acetaminophen-induced acute liver failure," *The Annals of Pharmacotherapy*, vol. 38, pp. 498–500, 2004.
- [47] E. Perez-Reyes, A. Casanova-Lara, E. Perez-Torres, and J. Cordova, [Reversal of acute liver failure with N-acetylcysteine and prednisone in a patient with DRESS syndrome: a case report and literature review]. *Revista de gastroenterologia de Mexico* 79, doi, 10.1016/j.rgm.2014.01.003, 1016.



Hindawi

Submit your manuscripts at
www.hindawi.com

